RYTM News and Press, Rhythm Pharmaceuticals Inc. From 04/01/24

2024-04-01 08:12:19 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals: Action Too Specific Rhythm Pharmaceuticals reports mixed Q4 results; initiates FY24 outlook Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals Read the full article on ...

BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it has signed an investment agreemen...

2024-03-26 07:37:54 ET More on Viking Therapeutics Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront Viking Therapeutics: Here To Stay In Obesity, Or A Flash In The Pan? Viking Therapeutics: VK2735 Data Supports A Buyout Jefferies start...

-- Three-part study to evaluate safety, tolerability and pharmacokinetics now underway -- -- RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies -- BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceutica...

2024-03-06 17:09:23 ET Summary Baker Brothers' 13F portfolio value decreased from $17.35B to $8.79B. The largest five stakes in the portfolio are Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Rhythm Pharma. New stakes include Cerevel Therapeutics, while stake disposals ...

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two ...

2024-02-23 06:03:58 ET Summary Rhythm Pharmaceuticals focuses on treating obesity caused by genetic mutations, but the market size for these mutations is too small to justify the company's valuation. Novo Nordisk's Ozempic also targets the same patient groups, making Rhythm's prod...

2024-02-22 23:33:09 ET Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2023 Earnings Conference Call February 22, 2024 08:00 AM ET Company Participants David Connolly - Executive Director, IR and Corporate Communications David Meeker - Chairman, President, and CEO Jennife...

2024-02-21 11:01:15 ET More on Rhythm Pharmaceuticals Rhythm completes screening for Phase 3 anti-obesity study Rhythm to acquire rights to Phase 2 anti-obesity drug from LG Chem Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals Historical earning...

2024-02-21 09:42:51 ET Major earnings expected before the bell on Thursday include: Dominion Energy ( D ) Iron Mountain ( IRM ) Moderna ( MRNA ) Newmont ( NEM ) Nikola ( NKLA ) Read the full article on Seeking Alpha For further details...